GUSHENGTANG(02273.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
GUSHENGTANG
02273.HK
Gushengtang Holdings Limited, an investment holding company, provides healthcare services in the People’s Republic of China. The company offers consultation, traditional massage, moxibustion, acupuncture, and other therapies. It is also involved in the wholesale of pharmaceutical products; and provision of investment management and supply chain management services. The company was formerly known as Gushengtang (Cayman) Ltd.
50.68 B
02273.HKMarket value -Rank by Market Cap -/-

Financial Score

19/01/2026 Update
B
Health Care ServicesIndustry
Industry Ranking1/28
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE14.93%A
    • Profit Margin11.15%B
    • Gross Margin30.63%C
  • Growth ScoreB
    • Revenue YoY16.83%B
    • Net Profit YoY32.21%B
    • Total Assets YoY16.73%A
    • Net Assets YoY3.94%C
  • Cash ScoreB
    • Cash Flow Margin896.66%B
    • OCF YoY16.83%B
  • Operating ScoreB
    • Turnover0.87B
  • Debt ScoreB
    • Gearing Ratio38.86%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CMB International's Investment Ratings and Target Prices for Pharmaceutical Stocks (Table)

    Zhao Yin International published a research report, listing the investment ratings and target prices for pharmaceutical stocks as follows: Stock | Investment Rating | Target Price (HKD) 3SBIO | Buy | 37.58 GUSHENGTANG | Buy | 44.95 WUXI XDC | Buy | 74 SINO BIOPHARM | Buy | 9.4

    AASTOCKS·
    HK
    02273
    -2.52%
    HK
    02268
    -2.47%
    HK
    01177
    -6.19%
    AASTOCKS·
    HK
    02273
    -2.52%
    HK
    02268
    -2.47%
    HK
    01177
    -6.19%

    CITIC International views the pharmaceutical sector's pullback as a rebalancing of industry valuation and performance, recommending 3SBIO and others

    Zhao Yin International believes that the correction in the pharmaceutical sector is a result of the rebalancing of valuation and performance, and the trend of innovative drugs going overseas will continue in the future. The U.S. "Biodefense Act" has limited impact on Chinese CXO companies. It recommends buying 3SBIO, GUSHENGTANG, WUXI XDC, and SINO BIOPHARM

    AASTOCKS·
    HK
    02268
    -2.47%
    HK
    01177
    -6.19%
    HK
    01530
    -5.51%
    AASTOCKS·
    HK
    02268
    -2.47%
    HK
    01177
    -6.19%
    HK
    01530
    -5.51%

    Gushengtang Holdings Repurchases 134,400 Shares at HKD 28.72 Each in HKEX Filing

    Gushengtang Holdings Ltd. repurchased 134,400 shares at HKD 28.72 each, totaling HKD 3,837,340, as disclosed in a filing with the Hong Kong Stock Exchange. The shares will be held as treasury shares.

    Reuters·
    HK
    02273
    -2.52%
    Reuters·
    HK
    02273
    -2.52%

    Gushengtang Holdings Files HKEX Disclosure on Repurchase of 366,700 Shares for HKD 10.42 Million

    Gushengtang Holdings Ltd. has disclosed the repurchase of 366,700 shares for HKD 10.42 million on the Hong Kong Stock Exchange. The repurchased shares will be held as treasury shares.

    Reuters·
    HK
    02273
    -2.52%
    Reuters·
    HK
    02273
    -2.52%

    Gushengtang Holdings Files HKEX Disclosure on 277,500 Share Buyback for HK$7.78 Million

    Gushengtang Holdings Ltd. disclosed a buyback of 277,500 shares for HK$7.78 million, filed with HKEX. The shares will be held as treasury shares. This information was published via HKEX's Issuer Information Service.

    Reuters·
    HK
    02273
    -2.52%
    Reuters·
    HK
    02273
    -2.52%
    © 2026 Longbridge｜Disclaimer